Want to see HK:2511 full AI Analyst Report?
2511 Stock Chart & Stats
HK$3.05
HK$0.00(0.00%)
At close: 4:00 PM EST
HK$3.05
HK$0.00(0.00%)
Day’s Range― - ―
52-Week RangeHK$1.80 - HK$4.72
Previous CloseN/A
Volume82.00K
Average Volume (3M)1.41M
Market Cap
HK$1.78B
Enterprise ValueHK$1.15K
Total Cash (Recent Filing)HK$502.94M
Total Debt (Recent Filing)HK$126.92M
Price to Earnings (P/E)―
Beta1.19
Next Earnings
Aug 31, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.50
Shares Outstanding571,325,700
10 Day Avg. Volume641,080
30 Day Avg. Volume1,410,076
Financial Highlights & Ratios
PEG Ratio0.13
Price to Book (P/B)4.14
Price to Sales (P/S)0.00
P/FCF Ratio-7.61
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.56
Revenue Forecast (FY)HK$3.00B
Bulls Say, Bears Say
Bulls Say
Balance-sheet RepairThe shift from negative to positive equity and materially improved leverage is a durable improvement to financial flexibility. It lowers near-term insolvency risk, improves access to capital markets and strategic optionality for partnering or R&D spend over the next 2–6 months.
Manageable Leverage LevelA debt-to-equity near 0.41 signals moderate leverage for a pre-revenue biotech and reduces immediate interest burden risk. This level supports runway extension and reduces refinancing strain versus prior higher-debt years, helping sustain operations while development progresses.
Improving Cash Burn TrendA measurable reduction in negative free cash flow suggests the company is slowing cash burn or improving operating efficiency. That trend lengthens runway, lowers near-term funding needs and reduces dilution risk if sustained across upcoming quarters.
Bears Say
No Reported RevenueZero reported revenue is a structural constraint: without commercial sales the company lacks operating cash generation and must rely on development milestones or external funding. This limits visibility on sustainable margins and long-term self-funding capability.
Persistent Cash BurnConsistent negative operating and free cash flow is a durable financing risk for a biotech. Ongoing burn requires recurring capital raises, which can dilute shareholders and create execution risk if market access tightens or milestones slip over the next several quarters.
Negative Returns & Rising Debt Step-upNegative ROE indicates invested capital is not producing returns, highlighting execution or commercialization gaps. Coupled with increased debt since 2023, this raises the chance of higher financing costs or covenant pressure if operating losses continue, constraining strategy.
Hightide Therapeutics Inc News
2511 FAQ
What was Hightide Therapeutics Inc’s price range in the past 12 months?
Hightide Therapeutics Inc lowest stock price was HK$1.80 and its highest was HK$4.72 in the past 12 months.
What is Hightide Therapeutics Inc’s market cap?
Hightide Therapeutics Inc’s market cap is HK$1.78B.
When is Hightide Therapeutics Inc’s upcoming earnings report date?
Hightide Therapeutics Inc’s upcoming earnings report date is Aug 31, 2026 which is in 13 days.
How were Hightide Therapeutics Inc’s earnings last quarter?
Hightide Therapeutics Inc released its earnings results on Mar 26, 2026. The company reported -HK$0.268 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Hightide Therapeutics Inc overvalued?
According to Wall Street analysts Hightide Therapeutics Inc’s price is currently Overvalued.
Does Hightide Therapeutics Inc pay dividends?
Hightide Therapeutics Inc does not currently pay dividends.
What is Hightide Therapeutics Inc’s EPS estimate?
Hightide Therapeutics Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Hightide Therapeutics Inc have?
Hightide Therapeutics Inc has 571,325,700 shares outstanding.
What happened to Hightide Therapeutics Inc’s price movement after its last earnings report?
Hightide Therapeutics Inc reported an EPS of -HK$0.268 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -1.613%.
Which hedge fund is a major shareholder of Hightide Therapeutics Inc?
Currently, no hedge funds are holding shares in HK:2511
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Hightide Therapeutics Inc Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
273.21%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
3.06%
Trailing 12-Months
Company Description
Hightide Therapeutics Inc
HighTide Therapeutics, Inc. operates as an investment holding company focused on the entire lifecycle from discovery to commercialization of innovative, multi-faceted therapeutic solutions. These solutions are specifically engineered to tackle metabolic and digestive disorders where current treatments fall short. The company's flagship pharmaceutical candidate, HTD1801, functions as a gut-liver anti-inflammatory metabolic modulator. It is being developed to address a range of severe conditions, including metabolic dysfunction-associated steatohepatitis, type 2 diabetes mellitus, severe hypertriglyceridemia, primary sclerosing cholangitis, and primary biliary cholangitis. Furthermore, HighTide's development pipeline includes HTD4010, a polypeptide medication for alcoholic hepatitis; HTD1804, designed to combat obesity; HTD1805, a versatile small molecule drug targeting various metabolic ailments; and HTD2802, intended for the management of inflammatory bowel disease. Established in 2011, HighTide Therapeutics, Inc. maintains its headquarters in Shenzhen, China.
Technical Analysis
CANbridge Pharmaceuticals Inc.
―
Mabpharm Limited
―
SinoMab Bioscience Ltd.
―
Transcenta Holding Limited
―
Cutia Therapeutics
―